NR1H4 and primary biliary cholangitis: As the most advanced agent in FXR agonists, obeticholic acid showed beneficial effects on hepatic cholestatic fibrosis and has been approved as the second-line treatment for primary biliary cholangitis (Lindor et al., 2019).